DOI 10.1016/j.semarthrit.2026.153054
Effectiveness and safety of upadacitinib on adult dermatomyositis: a cohort study in China.
Аннотация
OBJECTIVE
This retrospective study investigated the efficacy and safety of upadacitinib in adult patients with dermatomyositis (DM).
METHODS
Adult patients with DM who received upadacitinib between January 2024 and April 2025 were included and followed up for 6 months. Clinical data and complications were collected.
RESULTS
The cohort included 40 adult patients with DM, of whom 21 (52.5%) were female. The mean age was 46.93 ± 11.04 years. The median disease duration was 14 (8.25, 31) months. At baseline, the mean disease visual analog scale (VAS) score was 3.93 ± 1.75, and the mean daily glucocorticoid (GC) dose was 29.03 ± 17.02 mg. By the 3-month follow-up, the mean VAS score decreased to 2.57 ± 1.56 (p < 0.001), with significant improvements in cutaneous involvement, interstitial lung disease and manual muscle test 8 score (all p < 0.05). The mean daily GC dose was reduced to 17.66 ± 10.35 mg (p < 0.001). At 6 months, the mean VAS score further decreased to 1.74 ± 1.46 (p < 0.001). The mean daily GC dose was further reduced to 10.65 ± 5.97 mg (p < 0.001). Only four patients with anti-MDA5 antibody showed disease aggravation or relapsed in the cohort. Infection was the most common complication affecting 17 patients, including 6 patients with CMV viraemia and 3 patients with herpes zoster.
CONCLUSION
Upadacitinib may be a promising treatment option for adult DM, contributing to clinical improvement and GC dose reduction.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.